• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

byMinjee Kim
December 2, 2021
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A 5 mmHg reduction in systolic blood pressure was linked to an 11% risk reduction of new-onset type 2 diabetes.

2. ACE-inhibitors and ARBs were associated with a reduced risk of type 2 diabetes, while beta-blockers and thiazide diuretics increased the risk.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Management of the microvascular and macrovascular complications of type 2 diabetes often consists of controlling comorbid elevated blood pressures. However, it is not known whether controlling hypertension would decrease the risk for developing new-onset diabetes. This meta-analysis used patient data from previous randomized controlled trials of antihypertensive medications and evaluated the risk of developing type 2 diabetes. The study found that a 5-mmHg reduction in blood pressure was associated with a reduced risk for new-onset type 2 diabetes. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) were the most effective antihypertensives for reducing diabetes risk, while beta-blockers and thiazide diuretics increased the risk for diabetes. Calcium channel blockers did not have a significant effect on the development of diabetes. A limitation of this study includes the inability to determine whether low blood pressure is associated with a lower risk of diabetes or if certain medications improve diabetes risk through their own pharmacological mechanisms. For example, ACE inhibitors may lower inflammation in the body, which could help protect against diabetes not necessarily linked to hypertension. Nonetheless, this study illustrates the potential benefit of controlling high blood pressure on the risk of diabetes.

Click to read the study in the Lancet

Click to read an accompanying editorial in the Lancet

RELATED REPORTS

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

Relevant Reading:  Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.

In-Depth [meta-analysis]: This meta-analysis obtained randomized controlled trial data comparing antihypertensives in primary and secondary prevention programs from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC). Patients with pre-existing diabetes were excluded. The final cohort included 145 939 patients (60.6% men) across 19 trials with at least 1000 persons-years of follow-up data. Median follow-up was 4.5 years. There were 9883 patients diagnosed with diabetes during this follow-up time. This was calculated to be 16.44 (95% CI 16.01-16.87) events per 1000 person-years in the comparator group and 15.94 (15.47-16.42) in the intervention group. The comparator group was made up of placebo groups and less effective antihypertensives in the RCTs. A 5-mmHg reduction in systolic blood pressure resulted in an 11% reduction in risk for diabetes (hazard ratio 0.89 [95% CI 0.84-0.95]). In terms of specific antihypertensive classes, beta-blockers (relative risk 1.48 [1.27-1.74]) and thiazide diuretics (RR 1.20 [1.07-1.35]) were found to increase the risk of type 2 diabetes. In contrast, ACE inhibitors (RR 0.84 [0.76-0.93] and ARBs (RR 0.84 [0.76-0.92]) were found to reduce the risk of diabetes compared to placebo. There was no difference in risk between calcium channel blockers and placebo.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ACE inhibitorsangiotensin receptor blocker (ARB)antihypertensivesbeta blockerblood pressureblood pressure controlcalcium channel blocker (CCB)diabetesdiabetes mellitusdiabetes riskhypertensionhypertension controlhypertensive medicationssystolic blood pressurethiazide diuretictype 2 diabetesType 2 Diabetes Mellitus
Previous Post

Socioeconomic and ethnic inequalities are associated with greater risks for adverse pregnancy outcomes

Next Post

Wellness Check: Nutrition

RelatedReports

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications
StudyGraphics

#VisualAbstract: Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

August 10, 2022
#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes
StudyGraphics

#VisualAbstract: Treatment with dulaglutide improves glycemic control among youths with type 2 diabetes

August 9, 2022
Chronic Disease

Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes

August 2, 2022
Many new pediatric asthma cases attributable to obesity
Cardiology

Tirzepatide reduces body weight and improves cardiometabolic function in patients with obesity

July 22, 2022
Next Post
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets

Wellness Check: Nutrition

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Racial differences exist in emphysema prevalence in adults with normal spirometry findings
  • #VisualAbstract: Addition of selumetinib to radioactive iodine does not improve remission rates in differentiated thyroid cancers
  • MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.